RECRUITING Not applicable ClinicalTrials.gov

Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation

Sponsor: Seoul National University Hospital • ClinicalTrials.gov ID: NCT06699342

Registry updated: 2026-08-20

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study aimed to compare the clinical outcomes of left bundle branch area pacing combined with atrioventricular node ablation and pharmacologic treatment optimized according to guidelines in patients with symptomatic atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.

Interventions

Pacemaker implantation with Left bundle branch area pacing (LBBAP) (Procedure)
Left bundle branch pacing is a novel pacing modality that can bypass the pathological or disease-vulnerable region in the cardiac conduction system, to provide physiological pacing modality for patients. The procedure involves the implantation of a permanent pacemaker with a pacing lead positioned at the left bundle branch area to achieve physiological conduction system pacing. LBBAP-Pacemaker device and leads should be implanted according to the physician's standard practice.
Atrioventricular node ablation (AVNA) (Procedure)
Atrioventricular node ablation uses heat energy, called radiofrequency energy, to destroy the area between the upper and lower heart chambers. This area is called the atrioventricular node.
Pharmacologic therapy optimized for Atrial Fibrillation management (Drug)
Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation. Treatment is tailored based on patient tolerance and clinical efficacy.

Eligibility criteria

Inclusion: Patients who meet all of the following inclusion criteria 1)-6). 1. Permanent atrial fibrillation 2. Age ≥ 65 years 3. Refractory or intolerant to antiarrhythmic drugs, rate control medications, or catheter ablation 4. New York Heart Association (NYHA) functional class II- IV 5. LVEF \> 40% (within the past 3 months) 6. Patients with at least one of the following: 1. HF hospitalization (defined as HF as the major reason for hospitalization or treatment for HF lasting ≥12 hours and including treatment with intravenous (IV) diuretics at a healthcare facility) within 12 months 2. Elevated NT-proBNP (\>900 pg/ml) in the 30 days prior to enrollment Exclusion: Patients who meet at least one of the following exclusion criteria 1)-11). 1. Asymptomatic atrial fibrillation 2. Life expectancy to \< 12 months. 3. Primary moderate to severe valvular disease (except for functional mitral valve regurgitation or tricuspid valve regurgitation) 4. Mechanical tricuspid valve replacement 5. Severe chronic kidney disease (estimated Glomerular Filtration Rate ≤ 15 ml/1,73 m2 or receiving renal replacement treatment including hemodialysis or peritoneal dialysis) 6. Obstructive hypertrophic cardiomyopathy 7. Infiltrative cardiomyopathy (amyloidosis, sarcoidosis, Fabry disease, others) 8. Acute coronary syndrome or coronary revascularization (CABG or PCI) \<3 months 9. Severe primary pulmonary disease such as cor pulmonale, irreversible lung disease requiring inhalers, oxygen supplementation 10. Pacemaker/ICD/CRT treatment ongoing, or current pacemaker indication 11. Simultaneous participation in a different randomized clinical trial

Conditions

Atrial Fibrillation (AF)

Locations

Seoul National University Hospital — Seoul, Jongno-gu, South Korea

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment